Showing results (231-240 of 242) with videos related to
Sort By:
Pageof 25
Cancer Research|October 19, 2001
Regulation of human telomerase activity: repression by normal chromosome 3 abolishes nuclear telomerase reverse transcriptase transcripts but does not affect c-Myc activityA L Ducrest, M Amacker, Y D Mathieu, et al.Parasite Immunology|August 1, 1996
Human isotype antibody responses to an Onchocerca volvulus glutathione S-transferaseG Salinas, K Sinha, J P Cooper, et al.Cell|April 25, 1986
Role of conserved sequence elements 9L and 2 in self-splicing of the Tetrahymena ribosomal RNA precursorJ M Burke, K D Irvine, K J Kaneko, et al.British Heart Journal|April 1, 1995
How do the clinical findings in patients with pericardial effusions influence the success of aspiration?J P Cooper, R M Oliver, P Currie, et al.The British Journal of Dermatology|June 1, 1996
Systemic sclerosis associated with right ventricular cardiomyopathyA P Bewley, J P Cooper, N J Levell, et al.Drug Design and Discovery|May 1, 1997
Design and synthesis of small molecule interleukin-1 receptor antagonists based on a benzene templateR Sarabu, J P Cooper, C M Cook, et al.Basic Research in Cardiology|January 1, 1996
Impaired matching of perfusion and ventilation in heart failure detected by 133xenonN P Lewis, A P Banning, J P Cooper, et al.Pharmacoepidemiology and Drug Safety|April 3, 2008
Developing tools for the safety specification in risk management plans: lessons learned from a pilot projectAndrew J P Cooper, Sally Lettis, Charlotte L Chapman, et al.The EMBO Journal|December 18, 2001
A highly selective telomerase inhibitor limiting human cancer cell proliferationK Damm, U Hemmann, P Garin-Chesa, et al.Journal of Medicinal Chemistry|December 4, 1998
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituentJ E Cobb, S G Blanchard, E G Boswell, et al.Pageof 25